{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:29:46Z","timestamp":1790206186436,"version":"4.1.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2013,5,28]],"date-time":"2013-05-28T00:00:00Z","timestamp":1369699200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0063623","type":"journal-article","created":{"date-parts":[[2013,5,28]],"date-time":"2013-05-28T23:49:32Z","timestamp":1369784972000},"page":"e63623","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":88,"title":["Systematic Review of Antiretroviral-Associated Lipodystrophy: Lipoatrophy, but Not Central Fat Gain, Is an Antiretroviral Adverse Drug Reaction"],"prefix":"10.1371","volume":"8","author":[{"given":"Rene\u00e9","family":"de Waal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,5,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1097\/00002030-200304001-00017","article-title":"HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management","volume":"17","author":"A Carr","year":"2003","journal-title":"AIDS"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults","volume":"352","author":"S Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/cid\/cir324","article-title":"Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s","volume":"53","author":"GA McComsey","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1086\/605440","article-title":"Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA)","volume":"49","author":"E Negredo","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/01.qai.0000182230.47819.aa","article-title":"Fat Distribution in Men with HIV Infection","volume":"40","author":"P Bachetti","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1097\/00126334-200212153-00011","article-title":"Relationship Between HAART Adherence and Adipose Tissue Alterations","volume":"31","author":"A Ammassari","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref7","unstructured":"Higgins JPT, Green S, (editors) (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Cochrane Handbook website. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cochrane-handbook.org\" xlink:type=\"simple\">www.cochrane-handbook.org<\/ext-link>. Accessed 2012 May 23."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1097\/QAD.0b013e32833ac7a2","article-title":"Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy","volume":"24","author":"C Grunfeld","year":"2010","journal-title":"AIDS"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/157016211794582687","article-title":"Fat tissue distribution changes in HIV-infected patients treated with lopinavir\/ritonavir. Results of the MONARK trial","volume":"9","author":"S Kolta","year":"2011","journal-title":"Curr HIV Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e3181da1287","article-title":"Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses","volume":"55","author":"JL Lennox","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref11","unstructured":"Valantin MA, Flandre P, Kolta S, Duvivier C, Genin MA, <etal>et al<\/etal>.. (2010) Fat Tissue Distribution Changes in HIV-infected Patients with Viral Suppression Treated with Darunavir\/ritonavir (DRV\/r) monotherapy versus 2 NRTIs + DRV\/r in the MONOI-ANRS 136 Randomized Trial: Results at 48 weeks. Conference on Retroviruses and Opportunistic Infections. San Francisco."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e5647","DOI":"10.1371\/journal.pone.0005647","article-title":"Zidovudine\/lamivudine for HIV-1 infection contributes to limb fat loss","volume":"4","author":"MG van Vonderen","year":"2009","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/QAD.0b013e32832b4377","article-title":"Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment","volume":"23","author":"RH Haubrich","year":"2009","journal-title":"AIDS"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/QAI.0b013e3181aa12d5","article-title":"A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir\/lamivudine or tenofovir\/emtricitabine in HIV-1-infected patients with virological suppression","volume":"51","author":"E Martinez","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1086\/597776","article-title":"Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study","volume":"48","author":"G McComsey","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/644769","article-title":"Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial","volume":"49","author":"A Martin","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/QAD.0b013e328315a7a5","article-title":"Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults","volume":"22","author":"A Carr","year":"2008","journal-title":"AIDS"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/dkn278","article-title":"Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial","volume":"62","author":"C Duvivier","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1086\/589622","article-title":"A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy","volume":"198","author":"DW Cameron","year":"2008","journal-title":"J Infect Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/QAI.0b013e3181142d26","article-title":"Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384","volume":"45","author":"MP Dube","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/QAI.0b013e318042e204","article-title":"Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir\/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)","volume":"45","author":"P Tebas","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/QAI.0b013e31802bf122","article-title":"Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study","volume":"44","author":"D Podzamczer","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy","volume":"20","author":"GJ Moyle","year":"2006","journal-title":"AIDS"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/498505","article-title":"Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients","volume":"42","author":"JG Jemsek","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3851\/IMP2083","article-title":"A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity","volume":"17","author":"GJ Moyle","year":"2012","journal-title":"Antivir Ther"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/QAD.0b013e32834f3507","article-title":"Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy","volume":"26","author":"A Curran","year":"2012","journal-title":"AIDS"},{"key":"ref27","unstructured":"Feeney ER, Vrouenraets SME, Wit F, Brinkman K, Capel E, <etal>et al<\/etal>.. (2011) Switching Zidovudine to Tenofovir Improves Subcutaneous Adipose Tissue Volume and mtDNA Content. Conference on Retroviruses and Opportunistic Infections. Boston."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/QAI.0b013e3181ae2eb9","article-title":"A randomized comparative trial of continued zidovudine\/lamivudine or replacement with tenofovir disoproxil fumarate\/emtricitabine in efavirenz-treated HIV-1-infected individuals","volume":"51","author":"M Fisher","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1468-1293.2008.00606.x","article-title":"Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial","volume":"9","author":"MA Valantin","year":"2008","journal-title":"HIV Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.288.2.207","article-title":"Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial","volume":"288","author":"A Carr","year":"2002","journal-title":"JAMA"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00126334-200107010-00003","article-title":"Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study","volume":"27","author":"L Ruiz","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/jac\/dkp071","article-title":"Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110","volume":"63","author":"P Tebas","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/01.aids.0000183629.20041.bb","article-title":"Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides","volume":"19","author":"MP Dube","year":"2005","journal-title":"AIDS"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/135965350701200301","article-title":"The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients","volume":"12","author":"A Milinkovic","year":"2007","journal-title":"Antivir Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/aje\/kwj111","article-title":"The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM): Methods, Design, and Sample Characteristics","volume":"163","author":"PC Tien","year":"2006","journal-title":"Am J Epidemiol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QAI.0b013e3181b627dc","article-title":"Plasma Cytokine Levels in Tanzanian HIV-1-infected Adults and the Effect of Antiretroviral Treatment","volume":"52","author":"JM Haissman","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref37","first-page":"397","article-title":"Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and\/or dyslipidaemia","volume":"28","author":"GJ Thoni","year":"2002","journal-title":"Diabetes Metab"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/archinte.166.11.1225","article-title":"Effects of a Supervised Home-based Aerobic and Progressive Resistance Training Regimen in Women Infected With Human Immunodeficiency Virus. A Randomized Trial","volume":"166","author":"SE Dolan","year":"2006","journal-title":"Arch Int Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00002030-200402200-00013","article-title":"Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients","volume":"18","author":"SD Driscoll","year":"2004","journal-title":"AIDS"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/sj.clpt.6100140","article-title":"Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival","volume":"82","author":"SR Vlahakis","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2174\/157016210793499222","article-title":"Differential effects of efavirenz and lopinavir\/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines","volume":"8","author":"JM Gallego-Escuredo","year":"2010","journal-title":"Curr HIV Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/hep.24459","article-title":"Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy","volume":"54","author":"N Apostolova","year":"2011","journal-title":"Hepatology"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0063623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T19:53:12Z","timestamp":1688241192000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0063623"}},"subtitle":[],"editor":[{"given":"Jean-Luc E. P. H.","family":"Darlix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,5,28]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,5,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0063623","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718014456.793481151","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,28]]}}}